P2RY12 and diabetes mellitus: In DM patients, P2Y12 inhibitor monotherapy was associated with a favorable reduction in bleeding events (OR: 0.80, 95% CI: 0.64–1.05, p = 0.107, I2 = 22%, PHeterogeneity = 0.28).